Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

Journal of Virology

Volumn 78, Issue 21, 2004, Pages 12012-12021

  King, Nancy M ^a   Prabu Jeyabalan, Moses ^a   Nalivaika, Ellen A ^a   Wigerinck, Piet ^b   De Béthune, Marie Pierre ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; DARUNAVIR; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; URETHAN DERIVATIVE; VIRUS ENZYME;

ARTICLE; BINDING AFFINITY; CALORIMETRY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENTHALPY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; TITRIMETRY; VIRUS STRAIN;

BINDING SITES; CARBAMATES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROGEN BONDING; SULFONAMIDES; THERMODYNAMICS;

EID: 6344231715     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.21.12012-12021.2004     Document Type: Article

References (47)

1. Ala, P. J., E. E. Huston, R. M. Klabe, P. K. Jadhav, P. Y. Lam, and C. H. Chang. 1998. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry 37:15042-15049.
2. Arasteh, K., A. Clumeck, H. Pozniak, H. Jäger, M. De Pauw, H. Müller, M. Peeters, R. Hoetelmans, S. De Meyer, I. Van der Sandt, S. Comhaire, and R. Van der Geest. 2003. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI-experienced patients, abstr. 8.10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Mass.
3. Baldwin, E. T., T. N. Bhat, B. Liu, N. Pattabiraman, and J. W. Erickson. 1995. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2:244-249.
4. Brünger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
5. Chapman, M. S. 1995. Restrained real-space macromolecular refinement using a new resolution-dependent electron density function. Acta Crystallogr. A 51:69-80.
6. Chou, K.-C., A. G. Tomasselli, I. M. Reardon, and R. L. Heinrikson. 1996. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24:51-72.
7. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 257:483-489.
8. Collaborative Computational Project Number. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
9. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
10. de Béthune, M.-P., P. Wigerinck, H. Jonckheere, A. Tahri, L. Maes, R. Pauwels, and J. Erickson. 2001. TMC 114, a very potent protease inhibitor (PI) with an excellent profile against HIV variants highly resistant to current PI's, abst. F-1677. 41st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill.
11. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retrovir. 8:153-164.
12. De Meyer, S., H. Van Marck, J. Veldeman, P. McKenna, R. Pauwels, and M.-P. de Béthune. 2003. Antiviral activity of TMC114, a potent next-generation PI, against >4000 recent recombinant clinical isolates exhibiting a wide range of (PI) resistance profiles, abst. 17. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico.
13. De Meyer, S., H. Azijn, M. Van Ginderen, I. De Baere, R. Pauwels, and M.-P. de Béthune. 2002. In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed PIs, abst. 5. XI International HIV Drug Resistance Workshop, Seville, Spain.
14. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
15. Ferrin, T. E., C. C. Huang, L. E. Jarvis, and R. Langridge. 1988. The MIDAS display system. J. Mol. Graph. 6:13-27.
16. Ghosh, A., W. Thompson, P. Fitzgerald, J. Culberson, M. Axel, S. McKee, J. Huff, and P. Anderson. 1994. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. J. Med. Chem. 37:2506-2508.
17. Henderson, L. E., T. D. Copeland, R. C. Sowder, A. M. Schultz, and S. Oraszlan. 1988. Human retroviruses, cancer and AIDS: approaches to prevention and therapy. Liss, New York, N.Y.
18. Jones, T. A., M. Bergdoll, and M. Kjeldgaard. 1990. O: A macromolecular modeling environment, p. 189-195. In C. Bugg and S. Ealick (ed.), Crystallographic and modeling methods in molecular design. Springer-Verlag Press, Berlin, Germany.
19. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, et al. 1995. Crystal structure of HIV-1 protease in complex with vx-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
20. King, N. M., L. Melnick, M. Prabu-Jeyabalan, E. A. Nalivaika, S.-S. Yang, Y. Gao, X. Nie, C. Zepp, D. L. Heefner, and C. A. Schiffer. 2002. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11:418-429.
21. 20a. King, N. M., M. Prabu-Jeyabalan, E. A. Nalivaika, and C. A. Schiffer. 2004. Combatting susceptibility to drug-resistance: Lessons from HIV-1 protease. Chem. Biol., in press.
22. La Seta Catamancio, S., M. P. De Pasquale, P. Citterio, S. Kurtagic, M. Galli, and S. Rusconi. 2001. In vitro evolution of the human immunodeficiency virus type 1 Gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure. J. Clin. Microbiol. 39:1124-1129.
23. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
24. Minor, W. 1993. XDISPLAYF program. Purdue University. West Lafayette, Ind.
25. Morris, R. J., A. Perrakis, and V. S. Lamzin. 2002. ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr. D Biol. Crystallogr. 58:968-975.
26. Munshi, S., Z. Chen, Y. Yan, Y. Li, D. Olsen, H. Schock, B. Calvin, B. Dorsey, and L. Kuo. 2000. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr. D. Biol. Crystallogr. 56:381-388.
27. Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255.
28. Navaza, J. 1994. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50:157-163.
29. Nicholls, A., K. Sharp, and B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281-296.
30. Ohtaka, H., A. Velazquez-Campoy, D. Xie, and E. Freire. 2002. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11:1908-1916.
31. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
32. Pazhanisamy, S., J. Partaledis, B. Rao, and D. Livingston. 1998. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv. Exp. Med. Biol. 436:75-83.
33. Pettit, S. C., N. Sheng, R. Tritch, S. Erickson-Vitanen, and R. Swanstrom. 1998. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv. Exp. Med. Biol. 436:15-25.
34. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2000. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301:1207-1220.
35. Prabu-Jeyabalan, M., E. A. Nalivaika, N. M. King, and C. A. Schiffer. 2003. Viability of a drug-resistant HIV-1 protease variant: structural insights for better anti-viral therapy. J. Virol. 77:1306-1315.
36. Prabu-Jeyabalan, M., E. A. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.
37. Roberts, N. A. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl. 2):S27-S32.
38. Rose, J. R., R. Salto, and C. S. Craik. 1993. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem. 268:11939-11945.
39. Schock, H., V. Garsky, and L. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271:31957-31963.
40. Shafer, R. W., P. Hsu, A. K. Patick, C. Craig, and V. Brendel. 1999. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J. Virol. 73:6197-6202.
41. Shafer, R. W., D. Stevenson, and B. Chan. 1999. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27:348-352.
42. Sigurskjold, B. 2000. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal. Biochem. 277:260-266.
43. Todd, M. J., I. Luque, A. Velazquez-Campoy, and E. Freire. 2000. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39:11876-11883.
44. Valzaquez-Campoy, A., Y. Kiso, and E. Freire. 2001. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390:169-175.
45. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
46. Yoshimura, K., R. Kato, M. Kavlick, A. Nguyen, V. Maroun, K. Maeda, K. Hussain, A. Ghosh, S. Gulnik, J. Erickson, and H. Mitsuya. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.
47. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.